Valuation: Shield Therapeutics plc

Market Cap 65.17M 86.13M 75.52M 69.61M 122M 8.13B 125M 837M 324M 4.02B 323M 316M 13.92B P/E 2026 *
-277x
P/E 2027 * 8.27x
Enterprise Value 83.22M 110M 96.44M 88.89M 156M 10.38B 159M 1.07B 413M 5.13B 413M 404M 17.78B EV / Sales 2026 *
1.49x
EV / Sales 2027 * 1.01x
Free-Float
38.23%
Yield 2026 *
-
Yield 2027 * -
1 week-6.15%
Current month+2.52%
1 month+4.10%
3 months-25.61%
6 months-43.26%
Current year-38.07%
1 week 6
Extreme 6
6.7
1 month 5.7
Extreme 5.7
6.7
Current year 5.7
Extreme 5.7
12.5
1 year 2.7
Extreme 2.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
54.28
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 23/07/2024
Investor Relations Contact - -
General Counsel - 31/12/2025
Director TitleAgeSince
Director/Board Member 68 31/01/2016
Chairman 70 17/06/2020
Director/Board Member 59 25/06/2020
Date Insider Type Main position Quantity % Market Cap.
13/10/25Free

Chief Executive Officer

1,547,262 0.1485%
12/02/25Free

Chief Executive Officer

5,000,000 0.4800%
12/02/25Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.15%+114.04%-22.29% 86.13M
+2.06%+3.76%+21.48%-19.31% 63.09B
+0.74%+3.52%+53.14%+219.37% 55.61B
-3.10%+34.30%+34.30%+34.30% 41.64B
-2.36%-1.25%-52.13%-58.98% 38.98B
+6.97%+9.89%+70.21%-23.28% 29.82B
+12.59%+5.18%+144.26%-44.13% 23.71B
+5.78%+15.81%+60.64%+80.73% 21.48B
-1.25%-1.31%-4.39%+142.42% 16.87B
-0.81%+5.91%+67.70%+124.13% 16.74B
Average +2.06%+4.49%+50.92%+43.30% 30.8B
Weighted average by Cap. +1.77%+5.41%+37.63%+47.34%

Financials

2026 *2027 *
Net sales 55.68M 73.58M 64.52M 59.47M 104M 6.94B 107M 715M 277M 3.43B 276M 270M 11.9B 75.12M 99.28M 87.05M 80.24M 141M 9.37B 144M 964M 373M 4.63B 373M 365M 16.05B
Net income -74.5K -98.46K -86.33K -79.58K -140K -9.29M -143K -956K -370K -4.59M -370K -362K -15.92M 7.86M 10.39M 9.11M 8.4M 14.74M 980M 15.05M 101M 39.05M 484M 39.01M 38.16M 1.68B
Net Debt 18.05M 23.85M 20.92M 19.28M 33.85M 2.25B 34.55M 232M 89.66M 1.11B 89.57M 87.62M 3.86B 10.95M 14.47M 12.69M 11.7M 20.53M 1.37B 20.96M 141M 54.39M 675M 54.34M 53.15M 2.34B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
26/06/26 GBX 6.100 0.00% 256,950
25/06/26 GBX 6.100 -1.61% 810,762
24/06/26 GBX 6.200 -5.34% 1,307,548
23/06/26 GBX 6.550 0.00% 413,002
22/06/26 GBX 6.550 +0.77% 491,629
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0610GBP
Average target price
0.1667GBP
Spread / Average Target
+173.23%

Annual profits - Rate of surprise